168 related articles for article (PubMed ID: 15205208)
21. Phase I, dose-finding, and pharmacokinetic study of raltitrexed combined with oxaliplatin in patients with advanced cancer.
Fizazi K; Ducreux M; Ruffié P; Bonnay M; Daniel C; Soria JC; Hill C; Fandi A; Poterre M; Smith M; Armand JP
J Clin Oncol; 2000 Jun; 18(11):2293-300. PubMed ID: 10829050
[TBL] [Abstract][Full Text] [Related]
22. A phase I/II study of pemetrexed and vinorelbine in patients with non-small cell lung cancer.
Clarke SJ; Boyer MJ; Millward M; Underhill C; Moylan E; Yip D; White S; Childs A; Beale P; Latz J; Suri A; Iglesias JL
Lung Cancer; 2005 Sep; 49(3):401-12. PubMed ID: 15923057
[TBL] [Abstract][Full Text] [Related]
23. A phase I, dose-escalation trial of continuous- and pulsed-dose afatinib combined with pemetrexed in patients with advanced solid tumors.
Chu QS; Sangha R; Hotte SJ; Sergenson G; Schnell D; Chand VK; Hirte HW
Invest New Drugs; 2014 Dec; 32(6):1226-35. PubMed ID: 25037863
[TBL] [Abstract][Full Text] [Related]
24. A phase I study of pemetrexed, carboplatin, and concurrent radiotherapy in patients with locally advanced or metastatic non-small cell lung or esophageal cancer.
Seiwert TY; Connell PP; Mauer AM; Hoffman PC; George CM; Szeto L; Salgia R; Posther KE; Nguyen B; Haraf DJ; Vokes EE
Clin Cancer Res; 2007 Jan; 13(2 Pt 1):515-22. PubMed ID: 17255273
[TBL] [Abstract][Full Text] [Related]
25. Combination of oxaliplatin plus irinotecan in patients with gastrointestinal tumors: results of two independent phase I studies with pharmacokinetics.
Wasserman E; Cuvier C; Lokiec F; Goldwasser F; Kalla S; Méry-Mignard D; Ouldkaci M; Besmaine A; Dupont-André G; Mahjoubi M; Marty M; Misset JL; Cvitkovic E
J Clin Oncol; 1999 Jun; 17(6):1751-9. PubMed ID: 10561212
[TBL] [Abstract][Full Text] [Related]
26. Phase I trial of vinflunine and pemetrexed in refractory solid tumors.
Sanoff HK; Davies J; Walko C; Buie L; Chiu WK; Ivanova A; O'Neil B; Stinchcombe TE; Keller K; Dees EC
Invest New Drugs; 2011 Feb; 29(1):131-6. PubMed ID: 19830387
[TBL] [Abstract][Full Text] [Related]
27. Phase I trials of pemetrexed.
Fossella FV; Gatzemeier U
Semin Oncol; 2002 Apr; 29(2 Suppl 5):8-16. PubMed ID: 12023787
[TBL] [Abstract][Full Text] [Related]
28. Pemetrexed/oxaliplatin for first-line treatment of patients with advanced colorectal cancer: a phase II trial of the National Surgical Adjuvant Breast and Bowel Project Foundation Research Program.
Atkins JN; Jacobs SA; Wieand HS; Smith RE; John WJ; Colangelo LH; Vogel VG; Kuebler JP; Cescon TP; Miller BJ; Geyer CE; Wolmark N
Clin Colorectal Cancer; 2005 Sep; 5(3):181-7. PubMed ID: 16197621
[TBL] [Abstract][Full Text] [Related]
29. Pemetrexed in advanced colorectal cancer.
Louvet C; de Gramont A
Oncology (Williston Park); 2004 Nov; 18(13 Suppl 8):56-62. PubMed ID: 15655939
[TBL] [Abstract][Full Text] [Related]
30. Phase I study of two different schedules of bortezomib and pemetrexed in advanced solid tumors with emphasis on non-small cell lung cancer.
Davies AM; Ho C; Metzger AS; Beckett LA; Christensen S; Tanaka M; Lara PN; Lau DH; Gandara DR
J Thorac Oncol; 2007 Dec; 2(12):1112-6. PubMed ID: 18090584
[TBL] [Abstract][Full Text] [Related]
31. Phase I study of pemetrexed and pegylated liposomal doxorubicin in patients with refractory breast, ovarian, primary peritoneal, or fallopian tube cancer.
Richards DA; Loesch D; Vukelja SJ; Wu H; Hyman WJ; Nieves J; Wang Y; Hu S; Shonukan OO; Tai DF
Invest New Drugs; 2011 Oct; 29(5):963-70. PubMed ID: 20352294
[TBL] [Abstract][Full Text] [Related]
32. Phase I trial and pharmacokinetic study of pemetrexed in children with refractory solid tumors: the Children's Oncology Group.
Malempati S; Nicholson HS; Reid JM; Blaney SM; Ingle AM; Krailo M; Stork LC; Melemed AS; McGovern R; Safgren S; Ames MM; Adamson PC;
J Clin Oncol; 2007 Apr; 25(12):1505-11. PubMed ID: 17442992
[TBL] [Abstract][Full Text] [Related]
33. Intermittent weekly high-dose capecitabine in combination with oxaliplatin: a phase I/II study in first-line treatment of patients with advanced colorectal cancer.
Scheithauer W; Kornek GV; Raderer M; Schüll B; Schmid K; Längle F; Huber H
Ann Oncol; 2002 Oct; 13(10):1583-9. PubMed ID: 12377646
[TBL] [Abstract][Full Text] [Related]
34. Phase 1a/1b and pharmacogenetic study of docetaxel, oxaliplatin and capecitabine in patients with advanced cancer of the stomach or the gastroesophageal junction.
Deenen MJ; Meulendijks D; Boot H; Legdeur MC; Beijnen JH; Schellens JH; Cats A
Cancer Chemother Pharmacol; 2015 Dec; 76(6):1285-95. PubMed ID: 26499900
[TBL] [Abstract][Full Text] [Related]
35. A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation.
Rinaldi DA; Kuhn JG; Burris HA; Dorr FA; Rodriguez G; Eckhardt SG; Jones S; Woodworth JR; Baker S; Langley C; Mascorro D; Abrahams T; Von Hoff DD
Cancer Chemother Pharmacol; 1999; 44(5):372-80. PubMed ID: 10501910
[TBL] [Abstract][Full Text] [Related]
36. Pemetrexed in combination with oxaliplatin as a first-line therapy for advanced gastric cancer: a multi-institutional phase II study.
Celio L; Sternberg CN; Labianca R; La Torre I; Amoroso V; Barone C; Pinotti G; Cascinu S; Di Costanzo F; Cetto GL; Bajetta E
Ann Oncol; 2009 Jun; 20(6):1062-7. PubMed ID: 19218305
[TBL] [Abstract][Full Text] [Related]
37. Dose-finding study of weekly 24-h continuous infusion of 5-fluorouracil associated with alternating oxaliplatin or irinotecan in advanced colorectal cancer patients.
Cals L; Rixe O; François E; Favre R; Merad L; Deplanque G; Laadem A; Juin P; Bereder JM; Bernardini D; Herait P
Ann Oncol; 2004 Jul; 15(7):1018-24. PubMed ID: 15205194
[TBL] [Abstract][Full Text] [Related]
38. A phase I open-label dose-escalation study of intravenous BI 2536 together with pemetrexed in previously treated patients with non-small-cell lung cancer.
Ellis PM; Chu QS; Leighl N; Laurie SA; Fritsch H; Gaschler-Markefski B; Gyorffy S; Munzert G
Clin Lung Cancer; 2013 Jan; 14(1):19-27. PubMed ID: 22658814
[TBL] [Abstract][Full Text] [Related]
39. Sunitinib combined with pemetrexed and cisplatin: results of a phase I dose-escalation and pharmacokinetic study in patients with advanced solid malignancies, with an expanded cohort in non-small cell lung cancer and mesothelioma.
Camidge DR; Blais N; Jonker DJ; Soulières D; Doebele RC; Ruiz-Garcia A; Thall A; Zhang K; Laurie SA; Chao RC; Chow LQ
Cancer Chemother Pharmacol; 2013 Feb; 71(2):307-19. PubMed ID: 23108697
[TBL] [Abstract][Full Text] [Related]
40. A dose escalation study of gemcitabine plus pemetrexed administered biweekly in patients with solid tumors.
Kalykaki A; Vamvakas L; Agelaki S; Kalbakis K; Vardakis N; Sfakiotaki G; Ignatiadis M; Saridaki Z; Karampeazis A; Mavroudis D; Georgoulias V
Oncology; 2006; 71(3-4):197-203. PubMed ID: 17641541
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]